INTRODUCTION {#s1}
============

Antiretroviral pre-exposure prophylaxis (PrEP) with daily oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) prevents acquisition of HIV infection in adults[@R1]--[@R4] and is recommended by the Centers for Disease Control and Prevention (CDC) in the United States as part of a comprehensive package of preventative measures for individuals at substantial risk of HIV acquisition.[@R5] FTC/TDF PrEP has an excellent safety profile and is well tolerated with subclinical effects on renal function[@R6] and bone mineral density.[@R7],[@R8]

FTC/TDF is also active against hepatitis B; however, concern has been raised that providing PrEP to individuals infected with hepatitis B could lead to hepatitis flares and injury, especially in the setting of suboptimal PrEP adherence or PrEP discontinuation.[@R9] This concern stems from data on HIV-hepatitis B virus (HBV) coinfected individuals with chronic hepatitis B infections and cirrhosis who have high rates of hepatitis flares, sometimes leading to hepatic failure if they discontinue treatment for HIV with agents that are dually active against both HIV and HBV.[@R10],[@R11]

The effect of PrEP use on hepatitis B infection is not well understood and most PrEP trials excluded participants with circulating HBV surface antigen at baseline.[@R2],[@R12] There are no reported cases of flares in HIV-uninfected persons with chronic hepatitis B infection who have discontinued FTC/TDF PrEP, although clinical experience with PrEP remains limited. Owing to the complexity of hepatitis B management, the CDC PrEP guidelines recommend that individuals positive for hepatitis B surface antigen be referred to a clinician who specializes in the treatment of hepatitis B before the initiation of PrEP.[@R5]

Furthermore, individuals susceptible to hepatitis B infection should be vaccinated,[@R5] but recent data from the National Health and Wellness Survey suggest that only 26.3% of adults and 34.2% of men who have sex with men (MSM) in the US have ever received a hepatitis B vaccine.[@R13] Although sparse, data on Latin American MSM cohorts also reveal low vaccination rates: only 7% in a cohort in Argentina reported ever receiving a hepatitis B vaccine.[@R14] Even when HIV-infected individuals were found to be susceptible for hepatitis B, only 25% were vaccinated in a multicenter study of HIV-positive MSM in the US.[@R15] PrEP delivery could offer an additional opportunity to evaluate hepatitis B serostatus and increase vaccination rates.

We sough to provide information about hepatitis B global epidemiology, vaccine uptake and the safety of PrEP use among hepatitis B-infected men who have sex with men (MSM) and transgender women in the Iniciativa Profilaxis Pre-Exposición (iPrEx) study.

METHODS {#s2}
=======

The iPrEx study randomized 2499 MSM to evaluate the safety and efficacy of once-daily oral FTC/TDF PrEP for HIV prevention.[@R2] Study visits were scheduled every 4 weeks after enrollment.[@R2] A secondary end point of the iPrEx study was the proportion of hepatic flares among subjects with active hepatitis B infection.

Hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis B surface antigen (HBsAg), and hepatitis C antibody were obtained at screening of all participants. In addition, hepatitis serologies were repeated at the time PrEP was stopped if HBV infection status was ambiguous at baseline or if the study participants were susceptible at baseline. Participants at screening who were positive for HBcAb and negative for HBsAb were also tested for HBcAb IgM (HBcAb IgM) to distinguish acute from chronic infection. Individuals were excluded from the trial if the HBcAb IgM was positive, if they had indications for HBV treatment based on local practice standards, or had elevations in liver function tests (LFTs), including alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin more than 2-fold the upper limit of normal (ULN) within 28 days of enrollment, or signs of hepatic cirrhosis. All participants with evidence of active hepatitis B infection were excluded from participation at sites in Brazil because of local concerns about safety and treatment monitoring requirements.

Hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb) were tested for in enrolled participants with a positive HBsAg and when the activity of HBV remained ambiguous after initial screening (ie, when HBcAb was positive, HBsAb was negative, and HBcAb IgM was negative). Participants with a positive HBsAg were followed up with a medical history and LFTs at weeks 4, 8, 12, 16, 20, and 24 after stopping study drugs to assess for flares. Participants were also tested for elevated LFTs if they had signs or symptoms of hepatitis during the study and when deemed clinically appropriate.

For enrolled individuals with a positive HBsAg at any time during the trial, HBV DNA was measured via polymerase chain reaction. A HBV genotype was obtained for all participants with measurable HBV DNA.

Narratives were constructed for participants who were randomized to the FTC/TDF arm and were found to have acute hepatitis B infection.

Participants found to be HBV susceptible at screening were offered vaccination starting at their enrollment visit or at any time thereafter during study participation. When warranted by local medical practice standards, sites tested for HBsAb after vaccination and could provide an additional vaccine dose if HBsAb titers were insufficient. Flares were to be managed by specialists in internal medicine at the study site or referred to local specialists. Nucleoside and nucleotide analogue reverse transcriptase inhibitors were available for treatment of hepatitis B flares at study sites.

In a subset of participants, blood plasma was tested for the presence of FTC and tenofovir (TFV), and peripheral blood mononuclear cells were tested for FTC triphosphate and TFV diphosphate.[@R16]

DEFINITIONS {#s3}
===========

Active hepatitis B was defined as either acute hepatitis B or chronic hepatitis B infection.

Acute hepatitis B was defined by HBcAb, HBcAb IgM and HBsAg positivity, and HBsAb negativity.

Chronic hepatitis B was defined by HBsAg and HBcAb positivity with HBsAb and HBcAb IgM negativity. Other hepatitis B designations are described in Table [1](#T1){ref-type="table"}. A hepatic flare was defined as an increase in AST or ALT to more than 5 times ULN at any visit or \>2.5 times ULN for 3 months, within 24 weeks of permanently discontinuing the study drug.

###### 

Interpretation of the Hepatitis B Panel at Baseline

![](qai-71-281-g001)

RESULTS {#s4}
=======

Screening {#s4-1}
---------

Four thousand nine hundred five individuals were screened for iPrEx. Baseline hepatitis B serologies were obtained from 4459 individuals (Table [2](#T2){ref-type="table"}).

###### 

Hepatitis B Serologies Among Individuals Who Screened for iPrEx

![](qai-71-281-g002)

According to self-report, only 23.4% (1038/4431) had ever received a hepatitis B vaccine of which less than half 45.7% (447/977) had received all 3 recommended vaccines. Vaccination rates varied widely by site (range: 20.6%--90.7%), with US and Brazilian sites reporting the highest rates (83%--91%) and the Andean sites reporting the lowest (21%--27%).

Enrollment {#s4-2}
----------

### Chronic HBV Cases {#s4-2-1}

Among 2499 enrolled participants, 12 (0.48%) (6 cases in each arm, mean age = 31 \[range: 20--54\] years) had chronic HBV infection, all with positive HBsAg and HBcAb, and negative HBsAb and HBcAb IgM. Five were from the Andes (4 from Peru and 1 from Ecuador), 4 from Thailand, 1 from South Africa, and 2 from the US. All tested negative for hepatitis C antibodies.

Chronic HBV Cases Randomized to FTC/TDF {#s4-3}
---------------------------------------

Of the 6 HBsAg-positive cases in the active arm, 5 were negative for HBeAg and positive for HBeAb, and 1 was positive for HBeAg and negative for HBeAb (Figs. [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}A). The HBV DNA at baseline ranged from 0 to 8849 copies per milliliter in HBeAg-negative participants and was 336,000,000 copies per milliliter in the HBeAg-positive participants at baseline. Of the 5 individuals with HBV genotypes obtained, 3 had genotypes obtained after some exposure to FTC/TDF PrEP, and none had evidence of antiviral drug resistance. (One participant randomized to the placebo arm had the 80P mutation with possible resistance to lamivudine and telbivudine). After drug discontinuation, 5 of 6 participants had LFTs performed at one or more post-stop follow-up visits (range: 6--7 visits). LFTs remained within normal limits at all post-stop visits for 5 of 6 participants, with no evidence of hepatic flares. In one participant randomized to FTC/TDF, grade 1 LFT elevations were seen at post-stop week 12 visit, with AST 61 (ULN 41) and ALT 90 (ULN 38); at the post-stop week 24 visit, AST was 37 and ALT was 60. These elevations did not meet protocol criteria for hepatic flares.[@R17] Post-stop testing was not available in 1 participant who moved away. All 6 participants had evidence of detected drug at one or more visits. One participant with HBV viral load suppressed on FTC/TDF later developed a HBV viral rebound to 24,703 copies at a time when no drug was detected before permanent study drug discontinuation. The transaminases from the same date were ALT = 44 and AST = 51. Overall, while on randomized treatment, HBV viral loads ranged from 0 to 6205 at time points with detected drug and 0 to \>3.41 × 10^9^ at time points with no detected drug.

![A-F, Hepatitis B virus and LFTs over time for the 6 participants with chronic hepatitis B randomized to FTC/TDF.](qai-71-281-g003){#F1}

![A, Cases of chronic hepatitis B infection randomized to FTC/TDF. B, Cases of acute hepatitis B infection randomized to FTC/TDF.](qai-71-281-g004){#F2}

Narratives for 2 Acute HBV Cases Randomized to Receive FTC/TDF {#s4-4}
--------------------------------------------------------------

A 25-year-old man was randomized to FTC/TDF and dispensed study drug at enrollment (Fig. [2](#F2){ref-type="fig"}B). This participant was hepatitis B susceptible at screening (all negative for HBsAg, HBcAb, and HBsAb) with normal LFTs. At week 4, the participant had elevated LFTs (AST = 205, ALT = 669), and serologies showed negative for HBsAg, HBsAb, HBeAg; positive for HBcAb, HBcAb IgM, HBeAb at that visit. LFTs normalized 2 weeks later, and by week 28, he developed positive HBsAb and positive total HBcAb suggesting resolution of infection with protective immunity. Enrollment specimens were retrospectively tested and found to have an HBV viral load of 30,684, no evidence of resistance, HBsAg positive, HBcAb negative, HBsAb negative, and normal LFTs.

A 35-year-old participant was randomized to FTC/TDF and dispensed study drug on the day of enrollment. At screening, the participant had normal AST/ALT (35/35), with serologies consistent with chronic HBV infection: positive for HBsAg, HBcAb, and HBeAg and negative for HBsAb, HBcAb IgM, and HBeAb. Testing at enrollment (15 days after his screening visit) indicated that his AST/ALT had increased to 214/304 (grade 3) before PrEP initiation. Eight days after enrollment, repeat LFTs at an interim visit indicated grade 4 elevations (ALT 1061, AST 1473), and PrEP was stopped. At that time, there was evidence of an acute HBV infection with interval appearance of detected HBcAb IgM and continuing positive HBsAg, HBcAb, positive HBeAg, and negative HBsAb and HBeAb. Eleven weeks later, his AST/ALT returned to normal, and he was restarted on study drug 3 weeks later. Retrospective analysis at enrollment revealed a HBV viral load \>3.41 × 10^9^ copies that was undetectable by week 24 and remained undetectable for the duration of participant\'s time in the study. During visits at study weeks 28 and 72, HBV serology showed interval loss of HBsAg and HBeAg and interval appearance of HBeAb, yet still no detectable HBsAb. The patient self-terminated his participation in the study early at week 80 citing time constraints.

Vaccine Uptake {#s4-5}
--------------

Of the 2499 enrolled participants, 1633 (65.4%) were eligible for hepatitis B immunization. One thousand five hundred eighty-seven (97.2%) participants received at least one hepatitis B immunization, and 1383 (84.7% of total eligible) participants received the complete series of 3 injections.

Vaccine Response {#s4-6}
----------------

Of the 1383 participants who received the complete hepatitis B vaccination series with 3 doses and post-vaccination serologic testing, 86.9% (1021/1175) developed immunity as measured by a positive HBsAb. 44.4% (12/27) and 74.5% (38/51) of the individuals who received 1 or 2 doses, respectively, developed immunity. Two individuals who did not attain immunity were administered a fourth dose. Neither individual developed subsequent immunity.

DISCUSSION {#s5}
==========

In this large multinational randomized placebo-controlled clinical trial of oral FTC/TDF for HIV PrEP, hepatitis B exposure was highly prevalent (\>25% of participants screened with evidence of prior or active infection). Although over 60% of the participants were HBV susceptible at screening, fewer than 25% had reported ever receiving an HBV vaccine. Among those who had received a vaccine, fewer than half had received all 3 doses recommended by the CDC[@R18]; this deficiency varied widely among the sites and was especially high in the Andes.

In contrast to low vaccination rates before the trial, vaccine uptake during the trial was excellent with over 97% of eligible participants receiving at least 1 dose and 85% receiving the complete series; the vaccine response rate (as reflected by HBsAb seroconversion) for those completing the series was 87%, consistent with the CDC data regarding vaccine immunogenicity.[@R19] The acute HBV infections that occurred during the study highlight how prevention through vaccination is imperative, and the low rates of global vaccination provide a clear opportunity for disease prevention. Engaging adult MSM and transgender women in PrEP programs may offer a unique opportunity to increase vaccination rates. Interestingly, there is also some evidence from a recent retrospective study that use of hepatitis B-active antiretroviral therapy for treatment of HIV (lamivudine, emtricitabine, and TFV) led to a lower incidence of hepatitis B acquisition than the use of antiretrovirals without hepatitis B activity.[@R20] This effect was especially apparent when TFV was used, which provides another protective benefit of FTC/TDF use and is consistent with our data, showing that no acute HBV infections occurred after 4 weeks on FTC/TDF; both cases of acute HBV infection that occurred in the placebo arm occurred later. These findings suggest that FTC/TDF might serve to prevent hepatitis B-susceptible people from acquiring hepatitis B before completion of the vaccine series.

Among the 12 participants enrolled in the study with chronic hepatitis B, almost all of those tested had no evidence of antiviral drug resistance (8/9). One isolate from a participant randomized to the placebo arm showed possible resistance to lamivudine and telbivudine. No participant had virus associated with resistance mutations against TFV, and no participants experienced a flare either during the trial or after drug discontinuation, although one participant whose LFTs were normal while on study drug developed a low-grade, asymptomatic, and self-limited elevation of the transaminases after PrEP discontinuation. The majority with chronic hepatitis B randomized to FTC/TDF (5 of 6) had visits when drug was detected followed by visits when no drug was detected, indicating inconsistent adherence, and yet, none experienced a hepatitis B flare. It is possible that flares were absent because individuals with evidence of liver dysfunction were excluded. The risk of flares with FTC discontinuation seems to be limited to people with advanced liver disease.[@R21]

Interestingly, TFV use in chronic hepatitis B in the setting of cirrhosis has led to regression of fibrosis.[@R22] Regarding the 2 cases of acute HBV infection within the FTC/TDF arm, 1 resolved with development of immunity and the other resolved clinically with loss of circulating antigen but remained HBsAb negative. It is not known whether this person may have a recurrence of HBV antigenemia after stopping PrEP.

The principal limitation of this study is the small number of enrolled participants with active HBV infection, which limits the ability to provide definitive conclusions regarding the safety of PrEP use in the context of HBV infection in MSM/TGW or conclusive guidance related to best practices. Our results are reassuring, however, in that none of the participants in iPrEx with chronic HBV infection developed a flare during intermittent use of PrEP and even after drug discontinuation.

We agree with the CDC that screening for HBsAg should occur before PrEP initiation; while most providers prescribing PrEP are compliant with most PrEP guidelines, only approximately 60% of providers are screening for HBV infection.[@R23] Obtaining HBsAg alone followed by HBV DNA (when available) for individuals with a positive HBsAg may be the only required testing before initiating PrEP, especially in resource-limited settings in which obtaining additional serologies may be more expensive than vaccination.

We did not find that testing for HBsAb, HBcAb, HBcAb IgM, HBeAb, or HBeAg added value for the purposes of assessing PrEP eligibility. Importantly, persons with isolated HBcAb (and negative HBsAg and HBsAb) were all HBV DNA negative with normal LFTs, indicating that this common pattern of serologies was consistent immunity from prior infection rather than active infection with a HBV mutant. Individuals with HBV infection who are interested in PrEP can be safely started on FTC/TDF, which will also provide excellent activity against HBV[@R24]; consistent adherence may be required to prevent development of resistance.

This experience, combined with prior evidence showing no hepatitis flares among 23 women during and after oral TDF PrEP,[@R12] demonstrates that PrEP can often be safely started and stopped in persons with HBV infection who do not have cirrhosis or transaminase elevations at PrEP initiation. As information is limited and treatment for HBV infection is complex, referral to a specialist is appropriate when available, especially for PrEP discontinuation. At that time, a separate decision regarding continuing FTC/TDF or switching management strategies for HBV infection must be reached.[@R5] Such a decision would be based on further testing to evaluate cirrhosis to determine the need for ongoing hepatitis B treatment.[@R25],[@R26]

Individuals infected with HBV should have monitoring of LFTs (and possibly HBV viral load where available) every 6--12 months while on PrEP to ensure that the emergence of HBV resistance to FTC/TDF has not occurred, a theoretical concern with suboptimal adherence.[@R5] Although TDF presents a high barrier to developing HBV drug resistance, especially when given as combination therapy,[@R27] inconsistent adherence due to intermittent dosing may lead to drug resistance,[@R28] yet no cases have been reported. We did not observe any TDF resistance during the iPrEx study during which adherence to the daily regimen occurred in a minority of participants.[@R2]
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